Press Release April 2017


April 2017

VuEssence Announces License Agreement with the National Institutes of Health

Tampa, FL – VuEssence Inc.‎ has entered into a license agreement with the National Institutes of Health to commercialize technologies related to the diagnosis of stroke and other conditions. The technologies were initially developed by researchers at the National Institutes of Health using advanced techniques for measuring gene expression in stroke patients.

“The licensing process involves multiple steps and it can be lengthy and challenging,” says Dr. Sallam, President of VuEssence. “We are very pleased that we were able to complete the process and that we now have an added opportunity to advance and help disseminate truly useful technologies that can improve patient care.”

Stroke remains a leading cause of death and disability in the United States and worldwide despite many advances in recognizing the early signs of stroke and better management and treatment for conditions that increase the risk for the disease.

VuEssence Inc. is in the early stages of developing molecular diagnostic devices based on cutting-edge gene analysis technologies. The license agreement will allow the company to further build on the progress already achieved in finding ways to improve the detection and assessment of stroke.

About VuEssence Inc.
VuEssence Inc. is a private medical device company based in the Tampa Bay area. The company focus is on developing specialized diagnostic devices that will help in the detection and management of stroke and other conditions.